Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants
Citation Manager Formats
Make Comment
See Comments

Abstract
Background and Objectives The use of over-the-counter laxatives is common in the general population. The microbiome-gut-brain axis hypothesis suggests that the use of laxatives could be associated with dementia. We aimed to examine the association between the regular use of laxatives and the incidence of dementia in UK Biobank participants.
Methods This prospective cohort study was based on UK Biobank participants aged 40–69 years without a history of dementia. Regular use of laxatives was defined as self-reported use in most days of the week for the last 4 weeks at baseline (2006–2010). The outcomes were all-cause dementia, Alzheimer disease (AD), and vascular dementia (VD), identified from linked hospital admissions or death registers (up to 2019). Sociodemographic characteristics, lifestyle factors, medical conditions, family history, and regular medication use were adjusted for in the multivariable Cox regression analyses.
Results Among the 502,229 participants with a mean age of 56.5 (SD 8.1) years at baseline, 273,251 (54.4%) were female, and 18,235 (3.6%) reported regular use of laxatives. Over a mean follow-up of 9.8 years, 218 (1.3%) participants with regular use of laxatives and 1,969 (0.4%) with no regular use developed all-cause dementia. Multivariable analyses showed that regular use of laxatives was associated with increased risk of all-cause dementia (hazard ratio [HR] 1.51; 95% CI 1.30–1.75) and VD (HR 1.65; 95% CI 1.21–2.27), with no significant association observed for AD (HR 1.05; 95% CI 0.79–1.40). The risk of both all-cause dementia and VD increased with the number of regularly used laxative types (p trend 0.001 and 0.04, respectively). Among the participants who clearly reported that they were using just 1 type of laxative (n = 5,800), only those using osmotic laxatives showed a statistically significantly higher risk of all-cause dementia (HR 1.64; 95% CI 1.20–2.24) and VD (HR 1.97; 95% CI 1.04–3.75). These results remained robust in various subgroup and sensitivity analyses.
Discussion Regular use of laxatives was associated with a higher risk of all-cause dementia, particularly in those who used multiple laxative types or osmotic laxative.
Glossary
- AD=
- Alzheimer disease;
- aHR=
- adjusted HR;
- BNF=
- British National Formulary;
- HR=
- hazard ratio;
- MgO=
- magnesium oxide;
- OTC=
- over the counter;
- PD=
- Parkinson disease;
- SES=
- socioeconomic status;
- SMD=
- standardized mean difference;
- TMAO=
- trimethylamine N-oxide;
- VD=
- vascular dementia
As a major cause of disability and dependency of older adults, dementia is one of the greatest global challenges for health and social care. The number of people living with dementia was estimated to be over 43.8 million worldwide in 2016 and is expected to rise exponentially to 152 million by 2050.1 With only 40% of dementia cases attributable to established modifiable risk factors, further identification of preventable risk factors has become a crucial priority for alleviating the global burden of dementia.2
Constipation affects 20% of the general population,3 40% of community-dwelling older adults, and 70% of nursing home residents.4,5 With an increasing trend in the use of laxatives,6,-,8 the Compound Annual Growth Rate of the global laxatives market is projected to rise by 5.5% from 2020 to 2028, starting from US$ 5.5 billion in 2019.9 In the United Kingdom, about 85% of people with constipation were treated with laxatives.10 Current British guidance recommends starting with bulk-forming laxatives or fecal softeners for constipation, and if the condition persists, adding or switching to osmotic or stimulant laxatives.11 As all laxatives are available over the counter (OTC), laxative abuse is common among middle-aged and older adults, especially those who take multiple medicines that may induce constipation or those who believe that daily bowel movements are necessary for good health (e.g., for weight loss).12 These individuals usually begin using laxatives when constipation first occurs and develop a habit of using them afterward.12 Stimulant laxatives, which have the most immediate effect, are the most frequent choice in laxative abuse.12
Use of laxatives can lead to a new steady state of gut microbiota composition and long-term changes in the adaptive immune response.13 Recent research has also suggested that gut dysbiosis can affect the modulation of nerve signaling and the production of numerous neurotransmitters (such as acetylcholine, serotonin, dopamine, and gamma-aminobutyric acid) for normal cognitive function.14 Disruptions of gut microbiota composition may also increase the production of intestinal toxins, such as lipopolysaccharides, which have been associated with amyloid deposition, regional inflammatory response, and neural damage in animal studies.14,15 These multiple pathways in the microbiome-gut-brain axis16 support a hypothesis that regular use of laxatives may be associated with the risk of dementia.
However, few population studies have investigated this association directly. A recent cohort study showed that magnesium oxide (MgO), a common type of osmotic laxatives, was associated with a lower risk of dementia.17 However, the small sample size and lack of comparisons between different types of laxatives in that study have limited its value in assessing the roles of laxatives in the development of dementia. To comprehensively examine whether the use and different types of laxatives are associated with the risk of dementia, we conducted a large population-based cohort study using data from the UK Biobank.
Methods
Data Source and Study Population
Data were from the UK Biobank, with nearly 500,000 volunteering participants aged 40–69 years across England, Wales, and Scotland recruited between 2006 and 2010. At baseline visit, data on demographics, lifestyle, and health status were collected at assessment centers through touchscreen questionnaires, verbal interviews, and physical measurements. Health-related outcomes are available through linked records from primary care, hospital inpatient, death, and cancer registers. All participants who had not been diagnosed with dementia by the time of recruitment were included in this study. The UK Biobank received ethical approval from the research ethics committee (REC reference for UK Biobank 11/NW/0382), and participants provided written informed consent.
Exposures
The primary exposure of interest was self-reported regular use of any type of laxatives in the touchscreen questionnaire and verbal interview at baseline. Participants were asked whether they were regularly taking specific common OTC treatments including medications for constipation. Regular use was defined as most days of the week for the last 4 weeks in the questionnaire. If a participant reported any regular medication intake, the names of the medication were recorded if available. Four main subtypes of laxatives for regular users, fecal softeners, bulk-forming laxatives, osmotic laxatives, and stimulant laxatives as defined by the British National Formulary (BNF), were analyzed.11
Outcomes
We used algorithmically defined health-related outcomes preprocessed by the UK Biobank, in which all-cause dementia and subtypes of dementia were ascertained through linkage to data from primary care, hospital admissions, and death registers during follow-up.18 Follow-up started from recruitment and ended at the time of incident dementia, death, loss to follow-up, or latest data update (March 2019), whichever occurred first. The primary outcome of interest was all-cause dementia. Two of its subtypes, namely Alzheimer disease (AD) and vascular dementia (VD), were examined as secondary outcomes. Other types of dementia were not analyzed separately in this study due to rare occurrence or unclear classification of dementia in the UK Biobank. The accuracy of using routinely collected health care data sets to identify incident dementia is high in terms of positive predictive value (80%–92%), sensitivity (78%), and specificity (92.0%–96.6%), whereas the positive predictive value is relatively low for subtype diagnoses (71% for AD and 44% for VD).19,20
Covariates
Based on previous reviews,21,-,23 4 groups of baseline covariates were considered in our adjustment models: (1) sociodemographics (age, sex, ethnicity [White vs non-White], education level [university degree or higher vs others], and socioeconomic status [SES]), (2) lifestyle factors (smoking status [never, former vs current smoking], alcohol consumption [never or occasionally drinking, ≤14 units of alcohol per week vs >14 units per week], dietary consumption of vegetables, fruit, fish [≥twice a week vs <twice a week], and processed/unprocessed meat [≤once a week vs >once a week], physical activities [moderate, high vs low, categorized according to World Health Organization recommendations],24 and body mass index), (3) medical conditions and family history (diabetes, heart attack, stroke, high blood pressure, Parkinson disease [PD], depression, cognitive function, and parental history of dementia), and (4) regular medication use (opioids, anticholinergic drugs, statins, steroids, calcium channel blockers, and antidiarrheal agents). SES was measured by Townsend Deprivation Index categorized into 5 quintiles. One serving of vegetable or fruit consumption was defined according to the recommendation in a comprehensive review.25 Medical conditions were self-reported except PD (defined by algorithm) and cognitive function (tested via reaction time). Anticholinergic drugs were defined according to a previous study,26 and other medications were defined based on BNF.11 Other variables were determined through baseline touchscreen questionnaires or algorithmically defined data if available. More descriptions about covariates are in eTable 1 (links.lww.com/WNL/C645).
Main Analysis
Baseline characteristics were presented as frequency (percentage) for categorical variables and mean (SD) for continuous variables. The standardized mean difference (SMD) was used to denote the magnitude of imbalance in baseline characteristics by regular use of laxatives and by missing data status. An absolute value of SMD greater than 0.1 indicated meaningful imbalance.27 Cox proportional hazards models with age as the time scale28 were used to estimate the hazard ratio (HR) and 95% CI for the association between regular laxative use and the risk of incident dementia (all-cause dementia, AD, and VD individually). The proportional hazards assumption was tested by visual inspection using Schoenfeld residuals.
Four sets of models with progressive adjustment for potential confounders were conducted: model 1 adjusted for sociodemographic variables, model 2 additionally adjusted for lifestyle factors, model 3 additionally adjusted for medical conditions and family history, and model 4 additionally adjusted for regular use of other medications. The fully adjusted Cox proportional hazards model (model 4) was used to examine the association between regular use of laxatives and the risk of incident dementia. Using model 4, we further performed subgroup analysis by age (<65 and ≥65 years), sex, SES (below and above median), ethnicity (White and non-White), and education levels (university degree or higher and below university degree).
STATA 16 statistical software was used for all analyses. The results from complete-case analyses, which excluded the participants with missing data of covariates, were presented as the main results.
Secondary Analysis
As regular use of laxatives is a proxy of chronic constipation, it is possible that the association between laxatives and dementia, if present, was attributable to, at least partly, the association between constipation and dementia. To examine this possibility, a direct comparison among different types of laxatives was conducted in the participants who were taking laxatives (all of them should have constipation and thus were more comparable in this regard) and reported the specific types of laxatives. This issue was not examined by restricting to people with constipation or adjusting for constipation in Cox regression models because the status of constipation was known for only tens of participants and inclusion of constipation and use of laxatives simultaneously in 1 model would lead to multicollinearity.
Another 3 sets of sensitivity analyses were also conducted. First, to rule out the possibility of reversal causality between regular use of laxatives and dementia, participants who developed any dementia within the first 2 years or 4 years were excluded in separate analyses. Second, to examine the potential effect of missing data, multiple imputations were conducted for missing data in covariates.29 Third, to eliminate the influence induced by death before potential dementia occurrence, Fine and Gray competing-risks regression models were used to calculate the subdistribution HR by treating death as a competing-risks event. Moreover, we categorized the outcome as early-onset dementia (diagnosis before age 65 years) and late-onset dementia (diagnosis after 65 years) and tested the associations of regular laxative use with early-onset dementia among the participants aged 65 years or less and late-onset dementia among the all the participants with early-onset dementia as censor.
Negative Control Outcome Analysis
A negative control outcome analysis was conducted to examine whether the association between laxative use and dementia in our main analysis could be due to residual confounding.30 Hip fracture was selected as the negative control outcome given that a similar set of confounders is shared by the relationships of laxative use with hip fracture and dementia, such as frailty and time-varying conditions, which were not fully captured in our study. According to relevant trials and observational research,31,32 hip fracture was expected not to be associated with laxative use in our analysis, and otherwise, it may indicate that the association of laxative use with dementia would be distorted by residual confounding.30 Hip fracture was identified using data from hospital inpatient admissions. People diagnosed with hip fracture before baseline assessment were further excluded from this analysis. An association between laxative use and hip fracture would suggest residual confounding in our main findings.
Data Availability
Data are available from the UK Biobank after submitting an application (ukbiobank.ac.uk/register-apply/). The syntax for conducting the analysis is available on request.
Results
Baseline Characteristics
We identified 502,229 eligible participants (Figure 1), 18,235 (3.6%) of whom reported regular use of laxatives at baseline visit. Laxative users were more likely to be women, have a higher SES, have a lower education degree, have a long-standing illness, and regularly take anticholinergic and opioid drugs (Table 1). They were also more likely to have less alcohol consumption, more weekly fruit consumption, and less processed meat consumption. The prevalence of stroke, high blood pressure, depression, poor overall self-health rating, and the uptake of calcium channel blockers, statins, and steroid drugs were higher in regular than nonregular users. Participants with missing baseline data tended to be non-White, have more comorbidities, and have more medications (eTable 2, links.lww.com/WNL/C645).
BMI = body mass index; SES = socioeconomic status.
Baseline Characteristics of the Study Population
Laxative Use and Dementia
Among 476,219 participants with complete baseline data, a total of 2,187 cases of all-cause dementia (including 824 AD and 450 VD) were recorded over a mean follow-up of 9.8 (SD 1.5) years. The mean age at all-cause dementia diagnosis was 67.1 (SD 8.1), 68.8 (SD 7.9), and 67.0 (SD 8.1) years for all participants, regular users of laxatives, and nonregular users, respectively. Compared with the nonregular use, the fully adjusted HR (aHR) for the association with regular laxative use was 1.51 (95% CI 1.30–1.75) for all-cause dementia, 1.65 (95% CI 1.21–2.27) for VD, and 1.05 (95% CI 0.79–1.40) for AD (Table 2).
Association Between Regular Laxative Use and Risk of All-Cause Dementia, Alzheimer Disease, and Vascular Dementia
Among 16,703 regular laxative users, 6,530 participants reported specific types of laxatives they were taking (5,800 participants used only 1 type of laxative, and 730 used 2 or more). The risk of all-cause dementia increased with the number of laxative types, with an aHR of 1.28 (95% CI 1.03–1.61) for use of single laxative type and 1.90 (95% CI 1.20–3.01) for combination use of 2 or more laxative types (p trend = 0.001, Table 3). In the comparison of each laxative type to the reference group, only osmotic laxative was found to be associated with a higher risk of all-cause dementia (aHR 1.64, 95% CI 1.20–2.24, Table 4). When these 2 analyses were performed for each type of dementia separately, the 95% CIs became much wider, and many point estimates were odd probably because of the much fewer outcome events. Despite so, the results for VD showed consistent trends to those for all-cause dementia, that is, the risk of VD increased with the number of laxative types (p trend = 0.04, Table 3) and was associated with osmotic laxative only (aHR 1.97; 95% CI 1.04–3.75, Table 4). Subgroup analyses showed that the associations between laxative use and the risk of dementia did not vary appreciably with age, sex, SES, ethnicity, and education (eFigures 1 and 2, links.lww.com/WNL/C645). Moreover, the association between laxative use and dementia did not vary considerably with a history of stroke and regular use of opioids, which indicated that the association between laxatives and dementia was not influenced by these factors (eFigures 1 and 2).
Association of Number of Laxative Types Used With the Risk of Dementia
Association of Regular Use of Specific Types of Laxatives With Risk of All-Cause Dementia, Alzheimer Disease, and Vascular Dementia
Sensitivity Analyses
When the comparison of different types of laxatives was restricted to participants who were taking laxatives regularly, using bulk-forming laxatives as the reference group, osmotic laxative was still significantly associated with all-cause dementia (aHR 2.10, 95% CI 1.20–3.69, eTable 3, links.lww.com/WNL/C645), indicating that the observed association between laxatives and dementia did not just reflect the association, if any, between constipation and dementia. Other sensitivity analyses also yielded similar findings to the main analyses, except that the association between laxative use and VD was attenuated when excluding participants diagnosed with all-cause dementia within the first 4 years of their follow-up (aHR 1.35; 95% CI 0.93–1.97, eTables 3–7). We also tested the associations of regular laxative use with early-onset dementia among the participants aged 65 years or less and late-onset dementia among all the participants with early-onset dementia as censor. Their associations with laxative use were similar (eTables 8 and 9).
Negative Control Outcome Analysis
In the negative control outcome analysis using the fully adjusted model, no significant difference was found for overall regular use (aHR 1.05; 95% CI 0.87–1.28, eTable 10, links.lww.com/WNL/C645), making it less likely that the observed associations between regular use of laxatives and all-cause dementia and VD were caused by residual confounding.
Discussion
In this 10-year follow-up study of 502,229 UK Biobank participants, we found that regular use of laxatives was associated with a higher risk of all-cause dementia and VD. For both outcomes, the risk increased with the number of regularly used laxative types and was more pronouncedly associated with osmotic laxative. Negative control outcome analysis and various sensitivity analyses suggested that the associations were not substantially influenced by confounding or reversal causality.
It might be speculated that the stronger association observed between osmotic laxative and dementia was caused, at least partly, by the association between constipation severity and dementia. Indeed, previous studies found a higher prevalence of constipation (19.2%) among patients with dementia in a cross-sectional study,33 and constipation was associated with dementia among patients with PD.34,35 However, according to the current British guidelines,11 osmotic laxative is recommended for mild to moderate constipation when fecal softener or bulk-forming laxative does not work, and stimulant laxatives are recommended for more severe constipation. If different types of laxatives would have just been a proxy for constipation severity, stimulant laxatives should have shown a stronger association with dementia than osmotic laxatives and others, which is not the case in this study. Therefore, the association between osmotic laxatives and dementia would be more likely to reflect the potential effects of the type of laxatives per se.
Although the exact mechanisms linking laxatives with dementia have yet to be investigated, 1 possible explanation is that laxatives can influence gut microbiome composition and cognitive function in the microbiome-gut-brain axis.16 A laboratory study showed lasting influence of an osmotic laxative on gut microbiome composition.13 The alteration to the gut microbiota may affect the production of numerous neurotransmitters for normal cognitive function and increase the production of intestinal toxins that associated with the inflammatory response.14 Laxatives may also disrupt the intestinal epithelial barrier and facilitate passage of gut microbial–derived neurotoxic metabolites into the CNS.36 Some microorganisms may then reach the brain in conditions of decreased barrier integrity,14 for example, in stroke, which has been recognized as a known risk factor for dementia, especially VD.37,38 Indeed, gut bacteria dysbiosis caused by laxatives could increase production of trimethylamine N-oxide (TMAO) and its entry to the blood.39 High plasma TMAO levels lead to platelet hyperactivity, thrombosis, vascular inflammation, and atherosclerosis that contribute to the pathology of stroke and VD.14,40,41 Moreover, despite the greater genetic contributions to risk of early-onset dementia, the above mechanism may apply to both early-onset and late-onset dementia.
Previous evidence in this regard was limited, with only 1 relevant study published to date. That study included 1,547 MgO users and 4,641 nonusers. Opposite to our findings, it found that use of this specific osmotic laxative was associated with lower risk of dementia (aHR 0.52; 95% CI 0.41–0.79).17 The study was based on insurance claims data, with MgO use defined as an incident MgO prescription. Unlike self-reported regular use in our study, an incident prescription of MgO is not necessarily equivalent to a regular intake of MgO. Moreover, the study only controlled for age, sex, and comorbidity, whereas our study further adjusted for other known important confounders (e.g., education, socioeconomic factors, and use of other medications) to reduce the impact of confounding.
This study investigated the association between laxative use and dementia, with a large study population, long-term follow-up, and control for potential confounders. However, there are several limitations that should be borne in mind when interpreting our findings. First, volunteer selection bias may exist in our study because the response rate at baseline in the UK Biobank was only 5.5%.42 However, many associations observed in other studies could be replicated in the UK Biobank,43 suggesting that selection bias, if existent in this study, is not greater than that in others. Second, as dementia in the UK Biobank was ascertained through linkage to the participants' health-related records, underrecording might have occurred. If underrecording occurred more in participants with no regular use of laxative due to fewer contact with health services (these participants seemed healthier in our study population), the association observed in this study would tend to be overestimated. However, subgroup analyses by long-standing illness and overall health rating (both of which related to the frequency of contact with health services) showed similar results across subgroups, which did not support that detection bias was a major problem in this study. In addition, the accuracy of diagnosis of dementia subtypes, AD and VD, is relatively lower in the UK Biobank. Thus, further studies on the association between laxatives use and dementia subtype are warranted. Third, as laxatives are OTC medications, it is not feasible to validate the self-report use of laxatives using medical records as a standard reference. However, a previous study found that self-reported medication use showed high validity in the general population in Scotland when compared with national prescribing data.44 In addition, because of unspecified types of laxatives and low incidence of dementia, this study could be insufficiently powered to investigate the associations between other types of laxatives than osmotic and dementia. Fourth, we could not adjust for time-varying confounding in our study given a limited number of people providing information on time-varying variables, which was a common problem of most cohort studies. If the status of laxative use of some participants switched overtime (from regular use to no use or the inverse), the association between laxatives and dementia observed in this study might have been underestimated because long-term uninterrupted use would putatively be even more strongly associated with the outcome. Fifth, data on potential confounders, such as dietary fiber intake, severity of constipation, and personal preference for taking laxatives (e.g., side effects, cost, and availability), were limited in the UK Biobank and thus not controlled in our analysis, which may lead to residual confounding. Sixth, we could not explicitly explore the dose-response relation between laxative use and risk of dementia, as dosage information was not available in the UK Biobank.
Previous studies mainly focused on short-term adverse events of laxatives.45 The findings of this study suggested that regular use of laxatives, even without short-term severe adverse events, may have the potential long-term risk of dementia, especially when it comes to osmotic laxatives and combination use of 2 or more types of laxatives. In fact, osmotic and stimulant laxatives are both not recommended for regular use, yet we still found many regular users of these medications in this study. Many patients with constipation may misuse laxatives because they tend to self-treat with OTC medications. Therefore, pharmacists and clinicians should be well placed in providing instructions for patients regarding the use of OTC medications for treating constipation. If the long-term side effect of laxatives on cognition is confirmed, medical professionals should also convey this information to stakeholders to reduce the risk of dementia due to misuse or overuse of laxatives. Instead of regular use of laxatives, constipation can be mitigated most of the time by lifestyle changes, such as increasing fluid intake, dietary fiber, and activity levels, which may also benefit brain health.46,-,48
Our main finding is the discovery of the association for the first time. Therefore, this finding requires confirmation by further studies before more actions should be taken. To give better estimates of the association for each laxative type, future studies on this topic should try to collect more accurate data on the types of laxatives and dementia and conduct more powerful analysis of the association for each laxative type. More studies are also needed to identify potential contributory factors or specific mechanisms that may be responsible for the observed associations in our study. If regular laxative use has a true causative association with dementia risk, future studies on the associations of laxatives with other chronic diseases, such as stroke, depression, and PD, which may insidiously develop through similar mechanisms in terms of inflammation and alternation of gut microbiota, are warranted.
In conclusion, regular use of laxatives was associated with a higher risk of all-cause dementia. This risk increased with the number of regularly used laxative types and was more pronouncedly associated with osmotic laxative. Further studies are needed to clarify whether the association between laxatives and dementia observed in our study is causal.
Study Funding
This work was supported by the National Natural Science Foundation of China (grant no. 72274193), the Shenzhen Science and Technology Program (grant no. KQTD20190929172835662), and the Strategic Priority Research Program of Chinese Academy of Sciences (grant no. XDB 38040200).
Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
Acknowledgment
The authors thank the UK Biobank participants. This research has been conducted using the UK Biobank resource under application number 80476.
Appendix Authors

Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by Shenzhen Science and Technology Program (Grant No. KQTD20190929172835662).
Submitted and externally peer reviewed. The handling editor was Associate Editor Linda Hershey, MD, PhD, FAAN.
- Received September 14, 2022.
- Accepted in final form January 6, 2023.
- © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
- 1.↵WHO. Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. WHO; 2019.
- 2.↵WHO. Dementia: A Public Health Priority. WHO; 2012. Accessed August 1, 2021. who.int/publications/i/item/dementia-a-public-health-priority.
- 3.↵
- 4.↵
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- 9.↵Acute Market Reports. Laxatives Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028. Acute Market Reports; 2020.
- 10.↵
- Shafe AC,
- Lee S,
- Dalrymple JS, et al
- 11.↵Joint Formulary Committee. BNF 80: September 2020-March 2021. Pharmaceutical Press; 2020.
- 12.↵
- 13.↵
- 14.↵
- 15.↵
- 16.↵
- 17.↵
- 18.↵UK Biobank Outcome Adjudication Group. Definitions of Dementia and the Major Diagnostic Pathologies, UK Biobank Phase 1 Outcomes Adjudication. UK Biobank; 2018.
- 19.↵
- 20.↵
- 21.↵
- 22.↵
- Yu JT,
- Xu W,
- Tan CC, et al
- 23.↵
- Peters R,
- Booth A,
- Rockwood K, et al
- 24.↵World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour. WHO; 2020:viii, 93 p. The Basque version is published by the Basque Government's Physical Activity and Sports Office. The Thai version is published by is the Ministry of Health in Thailand.
- 25.↵
- Mozaffarian D
- 26.↵
- 27.↵
- Mamdani M,
- Sykora K,
- Li P, et al
- 28.↵
- 29.↵
- 30.↵
- 31.↵
- 32.↵
- 33.↵
- 34.↵
- Camacho M,
- Macleod A,
- Maple-Grødem J, et al
- 35.↵
- 36.↵
- 37.↵
- 38.↵
- 39.↵
- 40.↵
- 41.↵
- 42.↵
- 43.↵
- Batty GD,
- Gale CR,
- Kivimäki M, et al
- 44.↵
- 45.↵
- 46.↵
- 47.↵
- 48.↵
Letters: Rapid online correspondence
- Reader Response: Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants
- Tomoyuki Kawada, Professor, Nippon Medical School
Submitted March 14, 2023 - Reader Response: Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants
- Kelly Suchman, Internal Medicine Resident, Department of Medicine, Long Island Jewish Medical Center Zucker School of Medicine at Hofstra/Northwell
- Virginia Gao, Leon Levy Neurology Research Fellow, Department of Neurology, Weill Cornell Medicine
- Yuying Luo, Gastroenterology Fellow, The Henry D. Janowitz Division of Gastroenterology, The Icahn School of Medicine at Mount Sinai
Submitted March 09, 2023
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.